ArticleBritish journal of cancer2015

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.

L Bazzola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.